Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL6503463

COc1ccc(-c2cc3ccccc3[nH]2)cc1.N

nearest known ligand 0.97

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.97
RAB9A P51151 8/20 0.97
NPC1 O15118 7/20 0.97
MAPT P10636 5/20 0.97
CASP3 P42574 2/20 0.97
SENP8 Q96LD8 2/20 0.97
SENP7 Q9BQF6 2/20 0.97
SENP6 Q9GZR1 2/20 0.97
MEN1 O00255 3/20 0.67
KMT2A Q03164 3/20 0.67
ALDH1A1 P00352 6/20 0.61
HPGD P15428 5/20 0.61
SMN1; SMN2 Q16637 4/20 0.61
LMNA P02545 1/20 0.61
CYP1A2 P05177 1/20 0.60
CYP2C9 P11712 1/20 0.60
CYP2C19 P33261 1/20 0.60
CCNB2 O95067 1/20 0.57
CDK1 P06493 1/20 0.57
CCNB1 P14635 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30047670 0.98 KDM4E (1.00) KDM4ERAB9ANPC1MAPTCASP3
SCHEMBL2682217 0.98 KDM4E (1.00) KDM4ERAB9ANPC1MAPTCASP3
SCHEMBL11661055 0.85 KDM4E (0.76) KDM4ERAB9ANPC1MAPTCASP3
SCHEMBL25455006 0.84 RAB9A (0.74) KDM4ERAB9ANPC1MAPTCASP3
SCHEMBL5053299 0.84 NPC1 (0.87) KDM4ERAB9ANPC1MAPTCASP3
SCHEMBL4264688 0.83 KDM4E (0.81) KDM4ERAB9ANPC1MAPTCASP3
SCHEMBL7945775 0.83 KDM4E (0.73) KDM4ERAB9ANPC1MAPTCASP3
SCHEMBL29737278 0.82 RAB9A (0.71) KDM4ERAB9ANPC1MAPTCASP3
SCHEMBL28208371 0.82 RAB9A (0.71) KDM4ERAB9ANPC1MAPTCASP3
SCHEMBL28416625 0.82 NPC1 (0.83) KDM4ERAB9ANPC1MAPTCASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6858739-B2 Indole and benzimidazole 15-lipoxygenase inhibitors WARNER-LAMBERT COMPANY (US) 2005-02-22 US disclosed
US-20040038943-A1 Indole and benzimidazole 15-lipoxygenase inhibitors CONNOR DAVID THOMAS (US) 2004-02-26 US disclosed
EP-1294686-A2 INDOLE DERIVATIVES AND THEIR USE AS 15-LIPOXYGENASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2003-03-26 EP disclosed
WO-2001096299-A2 INDOLE DERIVATIVES AND THEIR USE AS 15-LIPOXYGENASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038943-A1 Indole and benzimidazole 15-lipoxygenase inhibitors ALOX15, ALOX5, ALOX12 KDM4E 881/4885RAB9A 4162/4885NPC1 868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.